Automated measurement of sFlt1, PlGF and sFlt1/PlGF ratio in differential diagnosis of hypertensive pregnancy disorders

Hypertension in Pregnancy

Volumn 32, Issue 4, 2013, Pages 459-473

  Engels, Theresa ^a   Pape, Juliane ^b   Schoofs, Katharina ^a   Henrich, Wolfgang ^a   Verlohren, Stefan ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DRK KLINIKEN BERLIN WESTEND   (Germany)

Author keywords

Biomarker; Diagnosis; Hypertension; Preeclampsia.; Pregnancy

Indexed keywords

PLACENTAL GROWTH FACTOR; VASCULOTROPIN RECEPTOR 1;

ADULT; ARTICLE; AUTOANALYZER; CHEMILUMINESCENCE IMMUNOASSAY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FALSE POSITIVE RESULT; FEMALE; GESTATIONAL AGE; HELLP SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; PREECLAMPSIA; PROTEINURIA; SENSITIVITY AND SPECIFICITY;

ADULT; AUTOMATION, LABORATORY; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; PREGNANCY; PREGNANCY PROTEINS; PROTEINURIA; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; YOUNG ADULT;

EID: 84884767966     PISSN: 10641955     EISSN: 15256065     Source Type: Journal    
DOI: 10.3109/10641955.2013.827205     Document Type: Article

References (31)

1. Ray JG, Vermeulen MJ, Schull MJ, Redelmeier DA. Cardiovascular health after maternal placental syndromes (CHAMPS): Population-based retrospective cohort study. Lancet 2005;366:1797-803
2. Hogberg U. The World Health Report 2005: ''make every mother and child count''-including Africans. Scand J Public Health 2005;33:409-11
3. Reinders LW, Mos CN, Thornton C, et al. Time poor: Rushing decreases the accuracy and reliability of blood pressure measurement technique in pregnancy. Hypertens Pregnancy 2006;25:81-91
4. Oliveira SM, Arcuri EA, Santos JL. Cuff width influence on blood pressure measurement during the pregnant-puerperal cycle. J Adv Nurs 2002;38:180-9
5. Sibai BM, Stella CL. Diagnosis and management of atypical preeclampsia-eclampsia. Am J Obstet Gynecol 2009;200:481e1-7
6. Zhang J, Klebanoff MA, Roberts JM. Prediction of adverse outcomes by common definitions of hypertension in pregnancy. Obstet Gynecol 2001;97:261-7
7. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649-58
8. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672-83
9. Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355:992-1005
10. Shibata E, Rajakumar A, Powers RW, et al. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-forgestational-Age neonates: Relationship to circulating placental growth factor. J Clin Endocrinol Metab 2005;90:4895-903
11. Chaiworapongsa T, Romero R, Espinoza J, et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol 2004;190:1541-7; discussion 1547-50
12. Staff AC, Braekke K, Harsem NK, et al. Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 2005;122:33-9
13. Robinson CJ, Johnson DD, Chang EY, et al. Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia. Am J Obstet Gynecol 2006;195:255-9
14. Chaiworapongsa T, Romero R, Kim YM, et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 2005;17:3-18
15. Romero R, Nien JK, Espinoza J, et al. A longitudinal study of angiogenic (placental growth factor) and anti-Angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008;21:9-23
16. Stepan H, Unversucht A, Wessel N, Faber R. Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension 2007;49:818-24
17. Schiettecatte J, Russcher H, Anckaert E, et al. Multicenter evaluation of the first automated Elecsys sFlt1 and PlGF assays in normal pregnancies and preeclampsia. Clin Biochem 2010;43:768-70
18. Verlohren S, Galindo A, Schlembach D, et al. An automated method for the determination of the sFlt1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 2010;202:161.e1-161.e11
19. Ohkuchi A, Hirashima C, Suzuki H, et al. Evaluation of a new and automated electrochemiluminescence immunoassay for plasma sFlt1 and PlGF levels in women with preeclampsia. Hypertens Res 2010;33:422-7
20. Stepan H, Schaarschmidt W, Jank A, et al. Use of angiogenic factors (sFlt1/PlGF ratio) to confirm the diagnosis of preeclampsia in clinical routine: First experience. Z Geburtshilfe Neonatol 2010;214:234-8
21. Brown MA, Lindheimer MD, de Swiet M, et al. The classification and diagnosis of the hypertensive disorders of pregnancy: Statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001; 20:IX-XIV
22. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 2002;77:67-75
23. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000;183:S1-22
24. Acharya G, Wilsgaard T, Berntsen GK, et al. Reference ranges for serial measurements of blood velocity and pulsatility index at the intra-Abdominal portion, and fetal and placental ends of the umbilical artery. Ultrasound Obstet Gynecol 2005;26:162-9
25. Taylor RN, Grimwood J, Taylor RS, et al. Longitudinal serum concentrations of placental growth factor: Evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol 2003;188:177-82
26. Woolcock J, Hennessy A, Xu B, et al. Soluble Flt-1 as a diagnostic marker of preeclampsia. Aust N Z J Obstet Gynaecol 2008;48:64-70
27. Sunderji S, Gaziano E, Wothe D, et al. Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: A prospective clinical study. Am J Obstet Gynecol 2010;202:40 e1-7
28. Salahuddin S, Lee Y, Vadnais M, et al. Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am J Obstet Gynecol 2007;197:28 e1-6
29. Masuyama H, Suwaki N, Nakatsukasa H, et al. Circulating angiogenic factors in preeclampsia, gestational proteinuria, and preeclampsia superimposed on chronic glomerulonephritis. Am J Obstet Gynecol 2006;194:551-6
30. Ohkuchi A, Hirashima C, Matsubara S, et al. Serum sFlt1:PlGF ratio, PlGF, and soluble endoglin levels in gestational proteinuria. Hypertens Pregnancy 2009;28: 95-108
31. Young B, Levine RJ, Salahuddin S, et al. The use of angiogenic biomarkers to differentiate non-HELLP related thrombocytopenia from HELLP syndrome. J Matern Fetal Neonatal Med 2010;23:366-70